NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03728556,A Study of CS1001 in Subjects With Stage III Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT03728556,,COMPLETED,"This is a randomized, double-blind, placebo-controlled, multicenter phase III study to evaluate the efficacy and safety of CS1001 in subjects with locally advanced/unresectable (Stage III) non-small cell lung cancer that has not progressed after prior concurrent/sequential chemoradiotherapy.",NO,Non-Small Cell Lung Cancer Stage III,BIOLOGICAL: CS1001 monoclonal antibody|BIOLOGICAL: CS1001 placebo,"Progress Free Survival (PFS), The primary endpoint is the PFS of CS1001 versus placebo (evaluated by blinded independent central review(BICR) according to response evaluation criteria in solid tumors RECIST v1.1)., from the date of randomization to the first date of recorded progression or all-cause death, whichever comes first, assessed up to 30 months.",,,CStone Pharmaceuticals,,ALL,"ADULT, OLDER_ADULT",PHASE3,381,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",CS1001-301|CTR20181429,2018-10-26,2023-04-03,2023-04-03,2018-11-02,,2023-06-15,"Guangdong Provincial People's Hospital, Guangzhou, Guangdong, 510080, China",
